Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Gross Margin (2016 - 2026)

Cytosorbents filings provide 15 years of Gross Margin readings, the most recent being 73.68% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 533.0% to 73.68% in Q4 2025 year-over-year; TTM through Dec 2025 was 71.48%, a 156.0% increase, with the full-year FY2025 number at 71.48%, up 156.0% from a year prior.
  • Gross Margin hit 73.68% in Q4 2025 for Cytosorbents, up from 70.28% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 77.46% in Q2 2021 to a low of 44.6% in Q3 2022.
  • Median Gross Margin over the past 5 years was 70.57% (2025), compared with a mean of 67.35%.
  • Biggest five-year swings in Gross Margin: tumbled -3017bps in 2022 and later skyrocketed 1904bps in 2023.
  • Cytosorbents' Gross Margin stood at 71.04% in 2021, then fell by -14bps to 61.31% in 2022, then dropped by 0bps to 61.27% in 2023, then grew by 12bps to 68.35% in 2024, then increased by 8bps to 73.68% in 2025.
  • The last three reported values for Gross Margin were 73.68% (Q4 2025), 70.28% (Q3 2025), and 70.85% (Q2 2025) per Business Quant data.